Drug Profile


Alternative Names: HS-410; UM-UC-3-gp96-Ig-HLA-A1; vesigenurtacel-L

Latest Information Update: 10 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Miami
  • Developer Heat Biologics
  • Class Adjuvants; Cancer vaccines; Cell therapies; Heat shock proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 05 Jun 2017 Additional efficacy data from a phase II trial in Bladder cancer released by Heat Biologics
  • 11 May 2017 Discontinued - Phase-II for Bladder cancer (Monotherapy, Adjuvant therapy) in USA (Intradermal)
  • 11 May 2017 Heat Biologics terminated a phase II trial in Bladder cancer (Monotherapy, Adjuvant therapy) in USA due to change in priority and the company reallocating resources towards combination program (Intradermal) (NCT02010203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top